Dranitsaris G, Amir E, Dorward K. Biosimilars of biological drug therapies: regula-tory, clinical and commercial considerations. Drugs 2011;71:1527-36.
García-Arieta A, Morales-Alcelay S, Herranz M et al. Investigation on the need ofmultiple dose bioequivalence studies for prolonged-release...
Glantz LH, Annas GJ. Impossible? Outlawing state safety laws for generic drugs.N Engl J Med 2011;365:681-3.
Greene JA, Kesselheim AS. Why do the same drugs look different? Pills, tradedress, and public health. N Engl J Med 2011;365:83-9.
Midha KK, Rawson MJ, Hubbard JW. The role of metabolites in bioequivalence.Pharm Res 2004;21:1331-44.
Paixao P, Gouveia LF, Morais JA. An alternative single dose parameter to avoidthe need for steady-state studies on oral extended-release drug...
Van der Meersch A, Dechartres A, Ravaud P. Quality of reporting of bioequivalen-ce trials comparing generic to brand name drugs: a methodological...
, Salvador Postigo Mota 
